Aminoglycosides in hemodialysis patients: Is the current practice of post dialysis dosing appropriate?

Seminars in Dialysis

Volumn 22, Issue 3, 2009, Pages 225-230

  O'Shea, Stacey ^a   Duffull, Stephen ^b   Johnson, David W ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE;

CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; DOSE RESPONSE; GRAM NEGATIVE INFECTION; HUMAN; METHODOLOGY; MORTALITY; RENAL REPLACEMENT THERAPY; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

AMINOGLYCOSIDES; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67649586443     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2008.00554.x     Document Type: Review

References (63)

1. United States Department of Health and Human Services : USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda : National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006
2. Johnson DW, McDonald SP, Excell L, Livingston B, Shtangey V : Peritoneal dialysis. In : McDonald SP, Excell L (eds). ANZDATARegistry Report 2005. Adelaide, South Australia : Australia and New Zealand Dialysis and Transplant Registry, 2006 : 84 100
3. Johnson DW, Dent H, Hawley CM, McDonald SP, Rosman JB, Brown FG, Bannister KM, Wiggins KJ : Associations of dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand. Am J Kidney Dis, 2008 [Epub ahead of print]
4. Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG : Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol 15 : 477 486, 2004 (Pubitemid 38140790)
5. Amin NB, Padhi ID, Touchette MA, Patel RV, Dunfee TP, Anandan JV : Characterization of gentamicin pharmacokinetics in patients hemodialyzed with high-flux polysulfone membranes. Am J Kidney Dis 34 : 222 227, 1999 (Pubitemid 29362084)
6. Barclay ML, Begg EJ : Aminoglycoside toxicity and relation to dose regimen. Adverse Drug React Toxicol Rev 13 : 207 234, 1994
7. Swan SK : Aminoglycoside nephrotoxicity. Semin Nephrol 17 : 27 33, 1997 (Pubitemid 27045159)
8. Keller F, Borner K, Schwarz A, Offermann G, Lode H : Therapeutic aminoglycoside monitoring in renal failure patients. Ther Drug Monit 9 : 148 153, 1987 (Pubitemid 17078113)
9. Begg EJ, Barclay ML : Aminoglycosides - 50 years on. Br J Clin Pharmacol 39 : 597 603, 1995
10. Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, Swan K, Bennett WM : Drug Prescribing in Renal Failure: Dosage Guidelines in Adults. Philadelphia : American College of Physicians, 1999
11. Matsuo H, Hayashi J, Ono K, Andoh K, Andoh Y, Sano Y, Saruki K, Tanaka J, Yamashita M, Nakamura K, Kubo K : Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality. Antimicrob Agents Chemother 41 : 2597 2601, 1997 (Pubitemid 27524726)
12. Dang L, Duffull S : Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis. J Clin Pharmacol 46 : 662 673, 2006 (Pubitemid 43920231)
13. Teigen MM, Duffull S, Dang L, Johnson DW : Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol 46 : 1259 1267, 2006 (Pubitemid 44564355)
14. Kamel Mohamed OH, Wahba IM, Watnick S, Earle SB, Bennett WM, Ayres JW, Munar MY : Administration of tobramycin in the beginning of the hemodialysis session: a novel intradialytic dosing regimen. Clin J Am Soc Nephrol 2 : 694 699, 2007
15. Sowinski KM, Magner SJ, Lucksiri A, Scott MK, Hamburger RJ, Mueller BA : Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol 3 : 355 361, 2008
16. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL : Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43 : 1549 1555, 1999 (Pubitemid 29331226)
17. Gailiunas P Jr., Dominguez-Moreno M, Lazarus M, Lowrie EG, Gottlieb MN, Merrill JP : Vestibular toxicity of gentamicin. Incidence in patients receiving long-term hemodialysis therapy. Arch Intern Med 138 : 1621 1624, 1978
18. Fisman DN, Kaye KM : Once-daily dosing of aminoglycoside antibiotics. Infect Dis Clin North Am 14 : 475 487, 2000 (Pubitemid 30308107)
19. Drew RH : Consolidated once-daily aminoglycoside dosing with gentamicin and tobramycin. In : Calderwood SB (ed). Up to Date. Available at http://www.uptodate.com, accessed January 19, 2009
20. Craig WA : Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 : 1 10, 1998
21. Moore RD, Lietman PS, Smith CR : Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155 : 93 99, 1987 (Pubitemid 17225088)
22. Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande MA : Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis 158 : 7 12, 1988 (Pubitemid 18188994)
23. Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig WA : In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 157 : 287 298, 1988 (Pubitemid 18061241)
24. Craig WA, Redington J, Ebert SC : Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 27 (Suppl. C 29 40, 1991
25. Gudmundsson S, Einarsson S, Erlendsdottir H, Moffat J, Bayer W, Craig WA : The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model. J Antimicrob Chemother 31 (Suppl. D 177 191, 1993 (Pubitemid 23193764)
26. McDonald PJ, Wetherall BL, Pruul H : Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 3 : 38 44, 1981
27. Cars O, Odenholt-Tornqvist I : The post-antibiotic sub-MIC effect in vitro and in vivo. J Antimicrob Chemother 31 (Suppl. D 159 166, 1993 (Pubitemid 23193762)
28. Daikos GL, Jackson GG, Lolans VT, Livermore DM : Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis 162 : 414 420, 1990 (Pubitemid 20239957)
29. Daikos GL, Lolans VT, Jackson GG : First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 35 : 117 123, 1991
30. Gilleland LB, Gilleland HE, Gibson JA, Champlin FR : Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa. J Med Microbiol 29 : 41 50, 1989 (Pubitemid 19133422)
31. Barclay ML, Begg EJ, Chambers ST : Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrob Agents Chemother 36 : 1951 1957, 1992
32. Barclay ML, Begg EJ : Aminoglycoside adaptive resistance: importance for effective dosage regimens. Drugs 61 : 713 721, 2001 (Pubitemid 32507001)
33. Barclay ML, Begg EJ, Chambers ST, Peddie BA : The effect of aminoglycoside-induced adaptive resistance on the antibacterial activity of other antibiotics against Pseudomonas aeruginosa in vitro. J Antimicrob Chemother 38 : 853 858, 1996 (Pubitemid 26413721)
34. Barclay ML, Begg EJ, Chambers ST, Thornley PE, Pattemore PK, Grimwood K : Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother 37 : 1155 1164, 1996 (Pubitemid 26258061)
35. Blaser J, Stone BB, Groner MC, Zinner SH : Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 31 : 1054 1060, 1987 (Pubitemid 17099578)
36. Verpooten GA, Giuliano RA, Verbist L, Eestermans G, De Broe ME : Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 45 : 22 27, 1989 (Pubitemid 19047142)
37. Tran Ba HP, Bernard P, Schacht J : Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest 77 : 1492 1500, 1986 (Pubitemid 16047093)
38. Gatell JM, Ferran F, Araujo V, Bonet M, Soriano E, Traserra J, SanMiguel JG : Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother 31 : 1383 1387, 1987 (Pubitemid 17148307)
39. Moore RD, Smith CR, Lietman PS : Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 149 : 23 30, 1984 (Pubitemid 14179885)
40. Raveh D, Kopyt M, Hite Y, Rudensky B, Sonnenblick M, Yinnon AM : Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. QJM 95 : 291 297, 2002 (Pubitemid 34537761)
41. Prins JM, Weverling GJ, van Ketel RJ, Speelman P : Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Clin Pharmacol Ther 62 : 106 111, 1997 (Pubitemid 27327104)
42. Begg EJ, Barclay ML, Duffull SB : A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 39 : 605 609, 1995
43. Barclay ML, Duffull SB, Begg EJ, Buttimore RC : Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Aust N Z J Med 25 : 230 235, 1995
44. Kirkpatrick CM, Duffull SB, Begg EJ : Once-daily aminoglycoside therapy: potential ototoxicity. Antimicrob Agents Chemother 41 : 879 880, 1997
45. Ali MZ, Goetz MB : A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24 : 796 809, 1997 (Pubitemid 27193857)
46. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC : A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24 : 786 795, 1997 (Pubitemid 27193856)
47. Ferriols-Lisart R, Alos-Alminana M : Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 53 : 1141 1150, 1996 (Pubitemid 26151347)
48. Munckhof WJ, Grayson ML, Turnidge JD : A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 37 : 645 663, 1996 (Pubitemid 26134115)
49. Barza M, Ioannidis JP, Cappelleri JC, Lau J : Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 312 : 338 345, 1996 (Pubitemid 26049400)
50. Galloe AM, Graudal N, Christensen HR, Kampmann JP : Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 48 : 39 43, 1995
51. Hatala R, Dinh TT, Cook DJ : Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis 24 : 810 815, 1997
52. Hatala R, Dinh T, Cook DJ : Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 124 : 717 725, 1996
53. Zaske DE : Aminoglycosides. In : Evans WE, Schentag JJ, Jusko WJ (eds). Applied Pharmacokinetic Principles of Therapeutic Drug Monitoring, 3rd edn. Appl Ther 1 : 331 381, 2006
54. Dager WE : Aminoglycoside elimination in extended duration hemodialysis. Ann Pharmacother 40 : 783 784, 2006
55. Agarwal R, Cronin RE : Heterogeneity in gentamicin clearance between high-efficiency hemodialyzers. Am J Kidney Dis 23 : 47 51, 1994 (Pubitemid 24021747)
56. Halpren BA, Axline SG, Coplon NS, Brown DM : Clearance of gentamicin during hemodialysis: comparison of four artificial kidneys. J Infect Dis 133 : 627 636, 1976
57. Vercaigne LM, Ariano RE, Zacharias JM : Bayesian pharmacokinetics of gentamicin in a haemodialysis population. Clin Pharmacokinet 43 : 205 210, 2004 (Pubitemid 38293792)
58. Manley HJ, Bailie GR, McClaran ML, Bender WL : Gentamicin pharmacokinetics during slow daily home hemodialysis. Kidney Int 63 : 1072 1078, 2003 (Pubitemid 36315586)
59. Decker BS, Molitoris BA : Manifestations of and risk factors for aminoglycoside nephrotoxicity. In : Palevsky PM (ed). Up to Date, 16.2 edn. Available at http://www.uptodate.com, accessed January 19, 2009
60. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS : Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 100 : 352 357, 1984 (Pubitemid 14156536)
61. Smith CR, Moore RD, Lietman PS : Studies of risk factors for aminoglycoside nephrotoxicity. Am J Kidney Dis 8 : 308 313, 1986 (Pubitemid 17235075)
62. Prins JM, Weverling GJ, de Blok K, van Ketel RJ, Speelman P : Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 40 : 2494 2499, 1996 (Pubitemid 26367631)
63. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R : Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 39 : 650 655, 1995